Study for Safety , immunogenicity and efficacy of intramuscular administration of Haemophilus Influenzae type b conjugate vaccine manufactured by Masoondarou Co. (MAS-HibVAC) in 50 children and compare with foreign sample -

Trial Profile

Study for Safety , immunogenicity and efficacy of intramuscular administration of Haemophilus Influenzae type b conjugate vaccine manufactured by Masoondarou Co. (MAS-HibVAC) in 50 children and compare with foreign sample -

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Hib vaccine conjugate (Primary)
  • Indications Haemophilus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Masoondarou Biopharma
  • Most Recent Events

    • 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by Iranian Registry of Clinical Trials.
    • 09 May 2012 Status changed from not yet recruiting to recruiting as reported by Iranian Registry of Clinical Trials.
    • 19 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top